for the population, and numbers of participants for the treatment and placebo arms is estimated-vitamin D dosage and numbers of participants are varied to achieve desired hazard ratio significance, using information from two vitamin D RCTs on cancer incidence conducted in Nebraska with good agreement between the model estimates and reported hazard ratios. Further improvements to the conduct of vitamin D RCTs would be to start the trial with a moderate bolus dose to achieve the desired 25(OH)D concentrations, and bloodspot 25(OH)D assay use in summer and winter annually to monitor seasonal and long-term changes in 25(OH)D concentration and compliance, and to allow dosage adjustment for achievement of desired vitamin D status.
Introduction
Many important health benefits are known to be associated with higher 25-hydroxyvitamin D [25(OH)D] concentrations, including reduced risk of many cancers [1] , [2] . The Garland brothers first proposed a role for vitamin D in reducing cancer risk on the basis of a geographical ecological study of colon cancer mortality rates and annual solar radiation doses [3] . From the findings of single-country ecological studies, 15-20 cancers have incidence and/or mortality rates inversely correlated with solar UVB doses [1] . From observational studies, there are clear inverse correlations between serum 25(OH)D concentration and incidence of several cancers, including breast [4] , colorectal [4] , kidney [5] , lung [6] , pancreatic [7] , upper aerodigestive [8] , and total, cancer incidence [9] . The mechanisms through which vitamin D reduces risk of cancer incidence and increase survival are well known [1] , [10] . a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
However, confirming causality of the link between vitamin D and cancer riskrequires randomized controlled trials (RCTs) of vitamin D supplementation. Unfortunately, vitamin D RCTs, in general, do not support observational studies [11] , [12] . To date, vitamin D supplementation reduced cancer risk in only three RCTs: two studies involving postmenopausal women in Nebraska [13] , [14] , and the Women's Health Initiative, when the analysis was restricted to participants who had not taken vitamin D or calcium supplements before entering the trial [15] .
Robert Heaney pointed out that the improper design of vitamin D RCTs accounts leads to their predictable failure to confirm the results of observational studies, since their design was based on standard RCT models for pharmaceuticals rather than on guidelines appropriate for nutrients [16] , e.g., the drug model assumes that the only source of the agent is in the trial and that a linear dose-response relationship exists. However, vitamin D trials can satisfy neither assumption. Also, it is not vitamin D dose, per se, that affects health outcomes but rather vitamin D status over time [serum concentrations of 25(OH)D] and, to a lesser extent, serum 1,25-dihydroxyvitamin D. Heaney's guidelines, as applied to vitamin D, include:
• Ensure an understanding of the 25(OH)D concentration-health outcome relation of interest.
• Measure 25(OH)D concentrations of prospective participants.
• Aim to include only those with 25(OH)D concentrations near the low end of the relationship.
• Supplement those in the treatment arm with enough vitamin D 3 to increase 25(OH)D concentrations to the upper region of the relationship.
• Measure achieved 25(OH)D concentrations.
• Optimize conutrient status (such as calcium).
We here expand upon Heaney's guidelines for vitamin D RCTs for cancer, starting with a modeling study, followed by a comparison with results of two cancer vitamin D trials to date, and end by identifying appropriate ways to conduct such trials. The model developed uses existing data on baseline and achieved 25(OH)D concentrations, expected cancer incidence rates as a function of baseline and achieved 25(OH)D concentrations, and calculations of 95% confidence intervals (CIs) for various equal numbers of participant years in treatment and control arms.
Materials and methods
A model is developed based on the use of population distributions of baseline 25(OH)D concentrations, vitamin D 3 dosage used, and achieved 25(OH)D concentrations post-supplementation; looking at expected cancer cases for the population as a function of 25(OH)D concentration, and the odds ratios for the effects of vitamin D 3 supplementation as a function of the number of participant-years in treatment and control arms. This model is then evaluated by comparison of its predictions with findings from two RCTs showing benefits of vitamin D 3 supplementation on cancer incidence.
The 25(OH)D concentration-cancer incidence relation used is based on 11 breast cancer case-control studies from seven countries [4] , and the relationship is shown in Fig 1. . This value differs slightly from that in Fig 2 in [4] since in that figure, one nested case-control study was inadvertently included.
Many authors consider that case-control study findings may be confounded by reverse causation-i.e., low 25(OH)D concentration's being a result of the life-style, or of physiological disturbances associated with the disease, rather than a cause of the disease [11] . However, the results from 11 studies agree well, and odds ratios for case-control studies for breast and colorectal cancer align with a linear fit to the results from prospective studies with results plotted as a function of follow-up time. Both those facts argue against that contention [4] . That the results for breast cancer can be used as a proxy for all-cancer incidence is supported by the finding that in ecological studies of cancer mortality rates in the U.S. for two periods, 1950-1969 and 1970-1994 , the correlations with UVB doses are similar [17] . Also, reductions in incidence of total, breast, colorectal, and invasive breast cancers in the Women's Health Initiative study for women not taking vitamin D or calcium supplements prior to entry were similar [15] . However, should such differences emerge, this modeling study allows utilization of the available data. The population distributions of serum 25(OH)D concentrations were obtained from a cross-sectional study of Canadians [18] . The values for those aged 50-79 years are used in this paper as given in Table 3 of [19] . Although Canada is north of the U.S., the two countries have similar population means for serum 25(OH)D concentrations:~24-25 ng/mL (for SI units, in nmol/L, multiply by 2.5) for the U.S. [20] , compared with~24 ng/mL for Canada.
The model developed uses data on baseline and achieved 25(OH)D concentrations, expected cancer incidence rates as a function of 25(OH)D concentration, and calculations of the 95% confidence intervals (CIs) for various equal numbers of participant years in the treatment and control arms.
Achieved 25(OH)D concentrations were estimated using the data developed by GrassrootsHealth from 25(OH)D measurements on 3667 community-based participants in their voluntary measurement program [21] , where participants who had not been supplementing with vitamin D prior to entry had a 25(OH)D concentration measurement made [by blood-spot testing], before starting supplementation with vitamin D 3 and had 25(OH)D concentration remeasured after six months. The best fit curve for their data is shown in their Fig 3 [21] . The rise in 25(OH)D per 1000 IU/d of daily oral vitamin D 3 decreases from 13 ng/mL for a baseline 25(OH)D of zero, to 4 ng/mL for a baseline 25(OH)D of 28 ng/mL, and to 2 ng/mL at 140 ng/ mL. The reason that serum 25(OH)D concentration increases less on any specific dose, with higher basal 25(OH)D concentrations, is that expression and activity, of CYP24A1, the homeostatic enzyme that destroys 25(OH)D and calcitriol, increases with increases in serum 25(OH) D [22] . Table 1 , and all-cancer incidence rate for those aged 65-69 years, 1760/100,000/yr, were used, and those values, together with the 25(OH)D concentration-breast cancer incidence relationship given above, and the achieved 25(OH)D concentrations for various daily vitamin D 3 doses, [21] allow calculation of the number of cancer cases expected for various 25(OH)D concentrations (see Table 2 ).
In this model, the equation for the number of cases is:
where n i is the number of expected cancer cases for the n-th 25(OH)D concentration decile, r is the assumed population cancer incidence rate, N i is the number of participant years in the n-th decile, OR i is odds ratio calculated from the 25(OH)D concentration-breast cancer incidence rate relationship (as shown in Fig 1) , and S 1-10 (OR i ) is the sum of the OR i for all ten deciles. One can calculate the OR for cancer incidence, and their 95% CIs, using an online tool [http://www.vassarstats.net/odds2x2.html]. This tool uses as input variables the number of subjects found to develop the conditions of interest in the two arms of an RCT to calculate risk ratios and odds ratios along with their 95% confidence intervals. In our model, the condition is cancer incidence and the two groups in this case are the treatment and control arms.
Results
The number, N, of participant years in the treatment and control arms to achieve a statistically significant reduction in all-cancer incidence is calculated from baseline and achieved 25(OH) D concentrations and expected cancer rates for these concentrations. The odds ratio is then calculated for a series of N values, and the results used to obtain a best-fit curve, in this case a smooth fit to the data-then, where the upper 95% CI value fit crosses the value 1.00 determines N. Thus, achieving a significant result for a baseline 25(OH)D concentration of 14 ng/ mL and treatment with 2000 IU/d, resulting in an achieved 25(OH)D concentration of 34 ng/ mL would take about 1000 participants each in the treatment and control arms (Fig 3) . Starting with a baseline concentration of 26 ng/mL and achieving 42 ng/mL would increase the numbers per RCT arm to 4000 each (Fig 4) .
The Table 4 .
https://doi.org/10.1371/journal.pone.0176448.g002 total number of cancer cases predicted for each pair of baseline and achieved concentration, for use in the odds ratio calculator. For example,~1500 participant-years would be needed in each arm to achieve statistical significance for subjects in the lowest five deciles of baseline vitamin D status with 2000 IU/d vitamin D 3 (Table 3) , but~10,000 participant-years in each arm for subjects with baseline status in the upper five deciles (Table 4) . (Note that the calculations are based on the number of cancer cases per year; alternatively, the number of participants could be fixed and the number of cancer cases per year could be multiplied by the number of years.).
Two vitamin D RCTs report significant reductions in cancer incidence. The first was a 4-year trial involving postmenopausal women in Nebraska (Clinicaltrials.gov as NCT00352170) [13] .The trial had three arms: 1100 IU/d of vitamin D 3 plus 1450 mg/d of No significant reduction in cancer incidence was apparent for the group overall. However, if analysis was restricted to participants who had not taken vitamin D or calcium supplements before entry, the hazard ratio was 0.86 (95% CI, 0.78-0.96), and significant [15] . Amongst those participants, 633 cancer cases occurred among the 7891 participant-years in the treatment arm and 715 cancer cases among the 7755 participant-years in the control arm. Comparing the model calculations with the results from that last trial is impossible because the distribution of 25(OH)D concentration among the participants is unknown. However, the finding is generally consistent with the model for the lower 25(OH)D deciles ( Table 1) . [14] . Thus, treatment and control arms each encompassed~8000 participant-years. Assuming those subjects came mostly from the upper five deciles of baseline 25(OH)D concentrations found in the Canadian data, the 8000 participantyears completed would, the present model suggests, result in a hazard ratio of 0.73 (0.48-1.12) ( Table 5 ). Including calcium in the treatment, but not in the control arm, may have contributed to the suggestive result (discussed later).
Discussion
The results of this modeling study, inspired by Heaney's guidelines [16] , agree reasonably well with results from the Women's Health Initiative trial and the recent Nebraskan trial [14] , giving added confidence to both the model and those two RCT results.
Several observational studies and one RCT, suggest supplementation with vitamin D+calcium reduced cancer risk more than supplementation with vitamin D alone [24] , [13] , [25] , [26] . Thus, to determine the effect of vitamin D alone, either the effect of calcium supplementation alone has to be determined if calcium supplementation is given solely to the treatment arm, as was the case in the later Lappe study [13] , or both arms should receive calcium supplementation. The findings using the present modeling system should put to rest two ideas. One is that RCTs have not shown vitamin D supplementation to reduce cancer risk, as several earlier reviews have suggested [11] , [27] . The other is that vitamin D supplementation can yield no more than a 15% reduction in incidence of disease [28] .
Ideally, vitamin D RCTs would start with a moderate loading dose, in deficiency, to ensure early rises in serum 25(OH)D concentrations, towards the planned target concentration [29] . The rationale for doing this, is that reaching the 25(OH)D plateau from supplementation with 1000 or 2000 IU/d of vitamin D 3 can take up to 4 months [30] . The ideal design would also allow for the fact that response to vitamin D supplementation is related not only to baseline 25 (OH)D, which varies with season [20] , but also to personal genetic factors [31] , [32] , body weight [33] , and natural history of disease development, e.g. from early life [34] . In addition, investigators should consider including several 25(OH)D measurements for participants during the trial, [perhaps in late summer and late winter each year] to monitor the range of 25 (OH)D achieved, together with compliance, and because, in long-term trials, 25(OH)D concentrations may vary with many other factors [35] , [4] . Blood spot assays are inexpensive and convenient because they can be organized by mail [e.g. Heartland Assays LLC (Ames, IA) offers blood spot 25(OH)D assays using liquid chromatography-tandem mass spectrometry methodology-interassay coefficient of variation, 4.0% and intra-assay coefficient of variation<2.5%. [Andrew J. Makowski, Heartland Assays, LLC, personal communication, Jan. 30, 2017] .
Many vitamin D 3 RCTs aim to answer the question, 'Does supplementing the healthy population with a modest amount of vitamin D affect health outcomes?'Because many of the largescale trials underway rely on volunteers, they are likely to include people more interested in their health than the average person. Thus, those trials run the risk of being biased by the health of participants, as happened in observational studies on estrogen plus progestin use by postmenopausal women for cardiovascular disease risk reduction which supported their use, but a large-scale RCT found adverse effects, such as increased risk of cancer, that countered the benefits [36]. Several large-scale vitamin D RCTs underway will examine how vitamin D supplementation affects cancer incidence or progression (see, e.g., Table 3 
